Key Takeaways
- • Benchmark reiterated a Buy rating and $15.00 price target on Kamada Ltd. (NASDAQ: KMDA) following Q1 2026 results, signaling continued confidence despite prior earnings misses.
- • Kamada reported Q1 2026 revenues of $45.2 million, representing 3% year-over-year growth from $44.0 million in Q1 2025, indicating decelerating growth momentum from prior quarters.
- • Full-year 2026 guidance projects $200–$205 million in revenues (11–14% growth) and adjusted EBITDA of $50–$53 million (19–26% margin expansion), with management reiterating outlook after Q1 results.
- • Revenue growth is driven by proprietary plasma-derived therapeutics including Varizig, Kedrab/Kamrab, and Glassia royalties, alongside new Distribution segment product launches.
- • The company announced a $0.25 annual shareholder cash dividend and trades at a P/E ratio of 24.12 on a $504 million market capitalization.
Summary
Benchmark analyst Robert Wasserman reiterated a Buy rating and $15.00 price target on Kamada Ltd. (NASDAQ: KMDA) following the company's first-quarter 2026 results. The biotech firm, which specializes in plasma-derived protein therapeutics, reported Q1 revenues of $45.2 million, marking 3% year-over-year growth from $44.0 million in the prior-year quarter. While the company has experienced analyst rating misses in recent periods, management said Q1 results aligned with internal expectations, supporting the reiteration of its full-year 2026 outlook.
For fiscal 2026, Kamada projects revenues between $200 million and $205 million, representing 11% to 14% annual growth compared to 2025's $180.5 million in revenues (itself a 12% increase over 2024). The company also guided adjusted EBITDA of $50 million to $53 million, implying a 19% to 26% margin expansion versus 2025 performance. This guidance was maintained following Q1 results, indicating management confidence in its full-year trajectory despite the modest single-digit sequential growth observed in the opening quarter.
Kamada's revenue growth continues to be anchored by its proprietary product portfolio, including Varizig and Kedrab for rabies prophylaxis in the U.S. market, as well as Kamrab and Glassia (royalty revenue) in international markets. Additional momentum is being generated by new product launches within the company's Distribution segment. The stock currently trades at a P/E ratio of 24.12 on a market capitalization of $504 million. In a capital return measure, Kamada announced an annual shareholder cash dividend of $0.25 per share, providing income support to investors alongside the company's equity valuation and growth profile.
For fiscal 2026, Kamada projects revenues between $200 million and $205 million, representing 11% to 14% annual growth compared to 2025's $180.5 million in revenues (itself a 12% increase over 2024). The company also guided adjusted EBITDA of $50 million to $53 million, implying a 19% to 26% margin expansion versus 2025 performance. This guidance was maintained following Q1 results, indicating management confidence in its full-year trajectory despite the modest single-digit sequential growth observed in the opening quarter.
Kamada's revenue growth continues to be anchored by its proprietary product portfolio, including Varizig and Kedrab for rabies prophylaxis in the U.S. market, as well as Kamrab and Glassia (royalty revenue) in international markets. Additional momentum is being generated by new product launches within the company's Distribution segment. The stock currently trades at a P/E ratio of 24.12 on a market capitalization of $504 million. In a capital return measure, Kamada announced an annual shareholder cash dividend of $0.25 per share, providing income support to investors alongside the company's equity valuation and growth profile.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.